We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Applied Molecular Transport Inc | NASDAQ:AMTI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.263 | 0.263 | 0.263 | 0 | 01:00:00 |
From May 2022 to May 2024
By Sabela Ojea
Applied Molecular Transport Inc. said Thursday that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its AMT-101 drug, aimed at the treatment of inflammation pouchitis.
The biopharmaceutcial company said there are currently no FDA-approved products to treat pouchitis, a severe end-stage complication of ulcerative colitis.
The FDA's Orphan Drug Designation is granted to drugs intended to treat a rare disease or condition in the U.S.
At premarket trading, shares of Applied Molecular Transport were up 2.2% at 95 cents.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 10, 2022 08:55 ET (13:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Applied Molecular Transp... Chart |
1 Month Applied Molecular Transp... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
